HZNP - Horizon analysis finds Tepezza hearing events similar to that seen in late-stage studies

An analysis of post-marketing studies conducted by Horizon Therapeutics (HZNP +1.9%) on Tepezza (teprotumumab) found that the rate of hearing-related adverse events was similar to that seen in phase 3 trials. Tepezza, approved in 2020, is the only FDA-approved therapy for thyroid eye disease. Post-marketing monitoring found that ~10% of incidents related to a safety database were a hearing-related event. That compares to 9.5% of patients treated with Tepezza in a phase 3 trial and an extension trial. In those two trials, 0% of patients reported hearing-related events. The findings were presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society. Read why Seeking Alpha contributor Out of Ignorance considers Horizon a hold.

For further details see:

Horizon analysis finds Tepezza hearing events similar to that seen in late-stage studies